Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT6PKBN)

• DTT Name: Proto-oncogene c-Src (SRC) DTT Info
• Gene Name: SRC

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[1]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[1]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[2]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[3]

11 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AL3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[4]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[4]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[5]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[6]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[7]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[9]
KX2-361	DML4H05	Brain cancer	2A00	Phase 1	[10]
PUR1800	DM6H10N	Chronic obstructive pulmonary disease	CA22	Phase 1	[11]
SUN-K0706	DMIF8RY	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[4]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

9 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aromatic bicyclic compound 1	DMVLQ2P	N. A.	N. A.	Patented	[13]
Aromatic bicyclic compound 2	DMKFV67	N. A.	N. A.	Patented	[13]
Aromatic bicyclic compound 3	DMRXN94	N. A.	N. A.	Patented	[13]
Aromatic bicyclic compound 4	DM3E75P	N. A.	N. A.	Patented	[13]
Aromatic bicyclic compound 5	DMALF06	N. A.	N. A.	Patented	[13]
Aromatic bicyclic compound 6	DM8L3KM	N. A.	N. A.	Patented	[13]
Deuterated 3-cyanoquinoline derivative 1	DM3Q9OX	N. A.	N. A.	Patented	[14]
PMID28460551-Compound-6	DMT7U1O	N. A.	N. A.	Patented	[15]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[16]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AP22408	DM5B72D	Osteoporosis	FB83.0	Terminated	[17]
PD166285	DMAOHXY	N. A.	N. A.	Terminated	[18]

98 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE	DM2XFGJ	Discovery agent	N.A.	Investigative	[19]
3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol	DMLYVPH	Discovery agent	N.A.	Investigative	[20]
4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine	DMI580M	Discovery agent	N.A.	Investigative	[21]
5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol	DMKXIWQ	Discovery agent	N.A.	Investigative	[21]
7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine	DMU74R8	Discovery agent	N.A.	Investigative	[20]
A-420983	DM7HSCI	Discovery agent	N.A.	Investigative	[22]
A-770041	DMP78JY	Discovery agent	N.A.	Investigative	[23]
Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr	DMH0SQC	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr	DMG19LW	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2)	DMORPDV	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr	DMK7YIG	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr	DMUWI2F	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr	DMNW7GR	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr	DMO4MYI	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr	DME4FZD	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2)	DM856JM	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe	DMU2PT1	Discovery agent	N.A.	Investigative	[24]
Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2)	DM4MP69	Discovery agent	N.A.	Investigative	[24]
AP-24163	DMVT6Y3	Discovery agent	N.A.	Investigative	[25]
AP-24226	DMGTEXD	Discovery agent	N.A.	Investigative	[25]
BAS-00387275	DMZPKGS	Discovery agent	N.A.	Investigative	[26]
BAS-00387328	DM4OSFD	Discovery agent	N.A.	Investigative	[26]
BAS-00387347	DMUF28Q	Discovery agent	N.A.	Investigative	[26]
BAS-00672722	DM6R4X8	Discovery agent	N.A.	Investigative	[26]
BAS-01047341	DMNB7CW	Discovery agent	N.A.	Investigative	[26]
BAS-01047655	DMC0FLB	Discovery agent	N.A.	Investigative	[26]
BAS-01373578	DMZBIC3	Discovery agent	N.A.	Investigative	[26]
BAS-0338868	DMZGLHJ	Discovery agent	N.A.	Investigative	[27]
BAS-0338872	DMZK0SC	Discovery agent	N.A.	Investigative	[27]
BAS-09534324	DMFMBZ9	Discovery agent	N.A.	Investigative	[26]
BAS-450225	DMTH1JQ	Discovery agent	N.A.	Investigative	[26]
BAS-4844343	DMFNAKU	Discovery agent	N.A.	Investigative	[26]
BMS-279700	DMOLCFQ	Discovery agent	N.A.	Investigative	[28]
CGP 77675	DMXH2R3	Discovery agent	N.A.	Investigative	[29]
CGP-191	DMCE6WJ	Discovery agent	N.A.	Investigative	[21]
CGP-62464	DMZ34P1	Discovery agent	N.A.	Investigative	[21]
Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr	DM67CAY	Discovery agent	N.A.	Investigative	[24]
Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe]	DMB2DV1	Discovery agent	N.A.	Investigative	[24]
Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr]	DMO5V9M	Discovery agent	N.A.	Investigative	[24]
Cysteine Sulfenic Acid	DM4GZUJ	N. A.	N. A.	Investigative	[30]
DPI59	DMTHZ3B	Discovery agent	N.A.	Investigative	[19]
Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu	DM6EA9B	Discovery agent	N.A.	Investigative	[31]
Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu	DMYZO37	Discovery agent	N.A.	Investigative	[31]
HKI-9924129	DM5LR2B	Gram-positive bacterial infection	1B74-1G40	Investigative	[32]
ISO24	DMU64W8	Discovery agent	N.A.	Investigative	[19]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[33]
K00244	DM2BKU8	Discovery agent	N.A.	Investigative	[34]
N-(4-(phenylamino)quinazolin-6-yl)acrylamide	DMI74KM	N. A.	N. A.	Investigative	[19]
N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine	DMGVJBD	Discovery agent	N.A.	Investigative	[28]
N6-Benzyl Adenosine-5'-Diphosphate	DM71MO2	Discovery agent	N.A.	Investigative	[35]
NG-25	DMC48D9	Discovery agent	N.A.	Investigative	[36]
NM-PP1	DMS8H5Q	Discovery agent	N.A.	Investigative	[9]
Oxalic Acid	DMLN2GQ	Discovery agent	N.A.	Investigative	[35]
PAS219	DML8BT7	Discovery agent	N.A.	Investigative	[19]
PASBN	DM7Y0G6	Discovery agent	N.A.	Investigative	[19]
PD-0166326	DMD2CG9	Discovery agent	N.A.	Investigative	[37]
PD-0173952	DMSCQ9U	Discovery agent	N.A.	Investigative	[32]
PD-0173955	DMOZEW9	Discovery agent	N.A.	Investigative	[32]
PD-0173956	DM8RW92	Discovery agent	N.A.	Investigative	[37]
PD-0173958	DMZQ8YV	Discovery agent	N.A.	Investigative	[32]
PD-0179483	DMKO8LE	Discovery agent	N.A.	Investigative	[32]
PD-174265	DMBHIAK	Discovery agent	N.A.	Investigative	[38]
PD173074	DMP0N4U	Nasopharyngeal carcinoma	2B6B	Investigative	[18]
Phenylphosphate	DMQ6P13	Discovery agent	N.A.	Investigative	[30]
Phosphonotyrosine	DM09MY1	Discovery agent	N.A.	Investigative	[35]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[39]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[40]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[41]
RU78191	DMOQE91	Discovery agent	N.A.	Investigative	[19]
RU78262	DMR8I03	Discovery agent	N.A.	Investigative	[19]
RU78299	DMXAK92	Discovery agent	N.A.	Investigative	[19]
RU78300	DM27BKD	Discovery agent	N.A.	Investigative	[19]
RU78783	DMU5H4K	Discovery agent	N.A.	Investigative	[35]
RU79072	DM9GQP0	Discovery agent	N.A.	Investigative	[19]
RU79073	DMWKTYC	Discovery agent	N.A.	Investigative	[19]
RU79256	DM06BGV	Discovery agent	N.A.	Investigative	[19]
RU81843	DMY3X6I	Discovery agent	N.A.	Investigative	[35]
RU82129	DMX7ZI0	Discovery agent	N.A.	Investigative	[35]
RU82197	DMJG4RC	Discovery agent	N.A.	Investigative	[30]
RU82209	DMR3A2O	Discovery agent	N.A.	Investigative	[35]
RU83876	DMNGKYF	Discovery agent	N.A.	Investigative	[35]
RU84687	DMWK3LU	Discovery agent	N.A.	Investigative	[19]
RU85053	DMOA8FK	Discovery agent	N.A.	Investigative	[35]
RU85493	DM97ZHX	Discovery agent	N.A.	Investigative	[35]
RU90395	DMHFKUC	Discovery agent	N.A.	Investigative	[35]
SBB007833	DMU8KGB	Discovery agent	N.A.	Investigative	[42]
SKS-927	DMGQ9Z5	Discovery agent	N.A.	Investigative	[43]
SU 6656	DMF1P6W	Discovery agent	N.A.	Investigative	[9]
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[44]
WH-4-023	DMJS8VQ	Discovery agent	N.A.	Investigative	[45]
Y-c[D-Pen-(2')Nal-GSFC]KR-NH2	DMAC65P	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2	DMEL4UN	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2	DM7P0H6	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2	DMBNM85	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2	DME1BGO	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2	DMF7S54	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2	DMW1PSO	Discovery agent	N.A.	Investigative	[46]
Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2	DM2ILAH	Discovery agent	N.A.	Investigative	[46]

References

• [1] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [2] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [3] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
• [8] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [9] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206).
• [11] Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
• [12] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [13] A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
• [14] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [15] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [16] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [17] Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9373-8.
• [18] Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35.
• [19] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [20] Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50.
• [21] Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9.
• [22] A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
• [23] Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
• [24] Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401.
• [25] 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56.
• [26] A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86.
• [27] Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11.
• [28] Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem. 2007 Jan 15;15(2):868-85.
• [29] A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49.
• [30] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [31] The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7(14):1909-1914 (1997).
• [32] Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
• [33] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [34] The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92.
• [35] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [36] Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.
• [37] Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6.
• [38] Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem. 2009 Jul 9;52(13):3915-26.
• [39] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [40] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [41] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
• [42] Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.
• [43] Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1358-61.
• [44] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
• [45] Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91.
• [46] Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.